Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Regenerx Biopharmaceuticals's shares outstanding for the quarter that ended in Mar. 2023 was 1.44 Mil.
Regenerx Biopharmaceuticals's quarterly shares outstanding
stayed the same
from Dec. 2022 (1.44 Mil) to Mar. 2023 (1.44 Mil).
Regenerx Biopharmaceuticals's annual shares outstanding
stayed the same
from Dec. 2021 (1.44 Mil) to Dec. 2022 (1.44 Mil).
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Regenerx Biopharmaceuticals Shares Outstanding (EOP) Related Terms
Regenerx Biopharmaceuticals Shares Outstanding (EOP) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RGRX vs MYMX, RGMP, NBRVF: Shares Outstanding (EOP) Comparison
For the Biotechnology subindustry, Regenerx Biopharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerx Biopharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regenerx Biopharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Regenerx Biopharmaceuticals's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
What does a Shares Outstanding (EOP) of 1.44 Mil mean?
Regenerx Biopharmaceuticals (RGRX) has a Shares Outstanding (EOP) of 1.44 Mil as of Mar. 2023. The total shares a company has outstanding, at period-end. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Shares Outstanding (EOP) too high?
Regenerx Biopharmaceuticals' current Shares Outstanding (EOP) is 1.44 Mil.
How does Regenerx Biopharmaceuticals' Shares Outstanding (EOP) compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Shares Outstanding (EOP) of 1.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current Shares Outstanding (EOP) is 1.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Shares Outstanding (EOP) of 1.44 Mil. The current Shares Outstanding (EOP) is 1.44 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Shares Outstanding (EOP) is 1.44 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGRX has been successfully added to your 